RU2758139C2 - Иммуноконъюгаты il2 и мутантного tnf - Google Patents

Иммуноконъюгаты il2 и мутантного tnf Download PDF

Info

Publication number
RU2758139C2
RU2758139C2 RU2019117750A RU2019117750A RU2758139C2 RU 2758139 C2 RU2758139 C2 RU 2758139C2 RU 2019117750 A RU2019117750 A RU 2019117750A RU 2019117750 A RU2019117750 A RU 2019117750A RU 2758139 C2 RU2758139 C2 RU 2758139C2
Authority
RU
Russia
Prior art keywords
ser
leu
gly
ala
thr
Prior art date
Application number
RU2019117750A
Other languages
English (en)
Russian (ru)
Other versions
RU2019117750A3 (enExample
RU2019117750A (ru
Inventor
Дарио Нери
Роберто ДЕ ЛУКА
Сара ВУЛЬХФАРД
Original Assignee
Филоджен С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1712916.4A external-priority patent/GB201712916D0/en
Application filed by Филоджен С.П.А. filed Critical Филоджен С.П.А.
Publication of RU2019117750A publication Critical patent/RU2019117750A/ru
Publication of RU2019117750A3 publication Critical patent/RU2019117750A3/ru
Application granted granted Critical
Publication of RU2758139C2 publication Critical patent/RU2758139C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2019117750A 2016-11-09 2017-11-08 Иммуноконъюгаты il2 и мутантного tnf RU2758139C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1618888.0 2016-11-09
GB201618888 2016-11-09
GB1712916.4 2017-08-11
GBGB1712916.4A GB201712916D0 (en) 2017-08-11 2017-08-11 IL2 and TNF mutant immunoconjugates
PCT/EP2017/078652 WO2018087172A1 (en) 2016-11-09 2017-11-08 Il2 and tnf mutant immunoconjugates

Publications (3)

Publication Number Publication Date
RU2019117750A RU2019117750A (ru) 2020-12-10
RU2019117750A3 RU2019117750A3 (enExample) 2021-04-01
RU2758139C2 true RU2758139C2 (ru) 2021-10-26

Family

ID=60413164

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019117750A RU2758139C2 (ru) 2016-11-09 2017-11-08 Иммуноконъюгаты il2 и мутантного tnf

Country Status (11)

Country Link
US (2) US11103592B2 (enExample)
EP (2) EP3896084A1 (enExample)
JP (1) JP6925431B2 (enExample)
AU (1) AU2017358578B2 (enExample)
CA (1) CA3043146C (enExample)
ES (1) ES2893249T3 (enExample)
MX (1) MX385819B (enExample)
NZ (1) NZ754407A (enExample)
RU (1) RU2758139C2 (enExample)
WO (1) WO2018087172A1 (enExample)
ZA (1) ZA201903387B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3502139A1 (en) 2017-12-19 2019-06-26 Philogen S.p.A. Antibodies to tumour antigens
EP3584258A1 (en) * 2018-06-19 2019-12-25 IEO - Istituto Europeo di Oncologia Srl Antibodies anti tumor associated antigens and method for obtaining them
KR102956533B1 (ko) 2018-07-02 2026-04-24 더 제너럴 하스피탈 코포레이션 항체 종양-표적화 조립 복합체
EP3660039A1 (en) * 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) * 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
JP7728701B2 (ja) 2018-12-17 2025-08-25 レビトープ リミテッド 双子型免疫細胞エンゲージャー
CA3138854A1 (en) 2019-05-02 2020-11-05 The General Hospital Corporation Teac and attac immunooncology compositions and methods
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP4185615A1 (en) 2020-07-22 2023-05-31 Philogen S.p.A. Treatment of pulmonary hypertension
KR102614063B1 (ko) * 2020-12-24 2023-12-19 대화제약 주식회사 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체
US20240390506A1 (en) * 2021-09-28 2024-11-28 Suzhou Fuse Biosciences Limited Immunoconjugates containing tnf-alpha and related methods and compositions thereof
US20250197485A1 (en) 2022-03-17 2025-06-19 Universitätsklinikum Jena Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2363707C2 (ru) * 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
WO2013045125A1 (en) * 2011-09-26 2013-04-04 Philogen S.P.A. Immunocytokine combination therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988006625A2 (en) 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US8623373B2 (en) 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
SI1817345T1 (sl) 2004-11-09 2009-10-31 Philogen Spa Protitelesa proti tenascinu-C
MX370565B (es) 2013-07-19 2019-12-17 Vib Vzw Miembros de la familia tnf modificados dirigidos.
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
GB201507908D0 (en) * 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2363707C2 (ru) * 2001-02-19 2009-08-10 Мерк Патент Гмбх Искусственные белки с пониженной иммуногенностью
WO2005087797A1 (en) * 2004-03-09 2005-09-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2013045125A1 (en) * 2011-09-26 2013-04-04 Philogen S.P.A. Immunocytokine combination therapy

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ARNAU J. et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, p.1-13; *
CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, v. 65, n. 10, p.1357-1369; *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, n.8, p.575-581; *
HALIN C. ET AL., Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha, CANCER RESEARCH, 2003, v. 63, n. 12, p.3202 - 3210 *
HALIN C. ET AL., Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha, CANCER RESEARCH, 2003, v. 63, n. 12, p.3202 - 3210; *
KONTERMANN R. E. et al., Bispecific antibodies, Drug Discovery Today, 2015, V. 7, N. 20, p.838-847; *
MAEDA Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 1997, v. 249, n. 2, p.147-152. *
OSTADE X VAN ET AL., Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis, EMBO JOURNAL, 1991, v. 10, n. 4, p.827 - 836; *
OSTADE X VAN ET AL., Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis, EMBO JOURNAL, 1991, v. 10, n. 4, p.827 - 836; ШИНГАРОВА Л.Н. и др., МУТАНТЫ ФАКТОРА НЕКРОЗА ОПУХОЛЕЙ ЧЕЛОВЕКА: ПОЛУЧЕНИЕ И НЕКОТОРЫЕ СВОЙСТВА, БИООРГАНИЧЕСКАЯ ХИМИЯ, 1996, Т. 22, Н. 4, с.243-251; KONTERMANN R. E. et al., Bispecific antibodies, Drug Discovery Today, 2015, V. 7, N. 20, p.838-847; *
PRETTO F. ET AL., Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy, CANCER IMMUNOLOGY, IMMUNOTHERAPY, 2014, v. 63, n. 9, p. 901 - 910; *
RUDIKOFF S. et al., Single amino acid substitution altering antigen-binding specificity, Proc Natl Acad Sci USA, 1982, v.79, n.6, p. 1979-1983; *
TOKURIKI N. ET AL., Stability effects of mutations and protein evolvability, Curr. Opin. Struct. Biol., 2009, v.19, n.5, p.596-604; *
TOKURIKI N. ET AL., Stability effects of mutations and protein evolvability, Curr. Opin. Struct. Biol., 2009, v.19, n.5, p.596-604; RUDIKOFF S. et al., Single amino acid substitution altering antigen-binding specificity, Proc Natl Acad Sci USA, 1982, v.79, n.6, p. 1979-1983; FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, n.8, p.575-581; ARNAU J. et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, p.1-13; CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, v. 65, n. 10, p.1357-1369; MAEDA Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 1997, v. 249, n. 2, p.147-152. *
ШИНГАРОВА Л.Н. и др., МУТАНТЫ ФАКТОРА НЕКРОЗА ОПУХОЛЕЙ ЧЕЛОВЕКА: ПОЛУЧЕНИЕ И НЕКОТОРЫЕ СВОЙСТВА, БИООРГАНИЧЕСКАЯ ХИМИЯ, 1996, Т. 22, Н. 4, с.243-251; *

Also Published As

Publication number Publication date
US20210369857A1 (en) 2021-12-02
MX2019005242A (es) 2019-09-10
AU2017358578A8 (en) 2019-07-04
US20200061203A1 (en) 2020-02-27
US11103592B2 (en) 2021-08-31
ES2893249T3 (es) 2022-02-08
NZ754407A (en) 2023-01-27
EP3538547B1 (en) 2021-07-07
EP3896084A1 (en) 2021-10-20
RU2019117750A3 (enExample) 2021-04-01
ZA201903387B (en) 2020-09-30
AU2017358578A1 (en) 2019-06-27
AU2017358578B2 (en) 2022-12-08
CA3043146C (en) 2021-11-23
JP6925431B2 (ja) 2021-08-25
WO2018087172A1 (en) 2018-05-17
RU2019117750A (ru) 2020-12-10
CA3043146A1 (en) 2018-05-17
MX385819B (es) 2025-03-18
EP3538547A1 (en) 2019-09-18
JP2019535315A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
US11274133B2 (en) IL2 and TNF immunoconjugates
US20210369857A1 (en) Il2 and tnf mutant immunoconjugates
US10858411B2 (en) IL22 immunoconjugates
AU2018392741B2 (en) Antibodies to tumour antigens
US20160200789A1 (en) Il4 conjugated to antibodies against extracellular matrix components
US20200270322A1 (en) Novel interleukin 4 immunoconjugates
WO2020249757A1 (en) Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP3660039A1 (en) Il2 immunoconjugates
HK40051742A (en) Immunoconjugates comprising il-2, anti-fibronectin antibody and mutant tnf-alpha